BioHarvest Sciences Strengthens Balance Sheet by $14.7 Million with Injection of $10.9 Million Gross Proceeds and Additional $3.8 Million in Debt Reduction

Rhea-AI Summary

BioHarvest Sciences (NASDAQ:BHST) has significantly strengthened its financial position through a series of transactions totaling $14.7 million in balance sheet improvements. The biotechnology company secured $10.9 million in gross proceeds through warrant exercises and convertible note issuances, while simultaneously reducing debt by $3.8 million.

The transactions included $5.8 million raised through warrant exercises, $5.1 million from new convertible notes, and various debt conversions and repayments. The company offered warrant holders and convertible loan holders a reduced price of $6.50 per share. Following these transactions, BioHarvest's total debt stands at $6.6 million.

The proceeds will fund capital expenditures for new capacity building, debt refinancing, and working capital requirements.

Positive

• None.

Negative

• Offered shares at $6.50, representing a discount to 90-day trading average
• Dilution of existing shareholders through issuance of new shares
• Still maintains $6.6 million in total debt post-transaction

News Market Reaction

+3.68% 3.4x vol

6 alerts

+3.68% News Effect

+19.1% Peak in 25 hr 33 min

+$7M Valuation Impact

$193M Market Cap

3.4x Rel. Volume

On the day this news was published, BHST gained 3.68%, reflecting a moderate positive market reaction. Argus tracked a peak move of +19.1% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $193M at that time. Trading volume was very high at 3.4x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the Company's balance sheet with an additional $10.9 Million in gross proceeds and a concurrent $3.8 Million reduction in total debt.

The following are the transactions which were executed subsequent to the Company's published Q2 2025 Financial Statements:

1. Successfully raised $5.8 Million in incremental cash through the exercising of 898,277 warrants;
2. Raised an additional $5.1 Million proceeds from the issuance of new Convertible Notes to multiple accredited investors that were subsequently converted into common shares;
3. Converted $1.8 Million of pre-existing Convertible Notes into common shares;
4. Repaid $1.4 Million of Long-Term Debt following lenders exercising 214,915 warrants; and
5. Repaid $0.6 Million of Short-Term Debt via the issuance of shares

The series of transactions were designed to deleverage the balance sheet and provide additional cash runway in support of the Company's continued growth. To achieve this objective, the Company offered existing warrant holders and convertible loan holders a short-term reduction of the warrant exercise price and convertible loan conversion price of $ 6.50, representing a modest discount to the 90-day trading average. This resulted in the majority of warrants' holders opting to exercise their rights and in lenders acting to convert their convertible notes. As a result, 1,113,192 warrants were exercised into 1,113,192 ordinary shares, $6.9 Million of convertible notes were converted into 1,058,261 ordinary shares and an additional 88,213 ordinary shares were issued in consideration of $0.6 Million short-term repayment.

Following this transaction, the Company has approximately $6.6 Million of Total Debt (Short Term debt of $3.6 Million, Long Term debt of $3 Million).

The gross proceeds from this transaction totalling $10.9 Million in cash will be used for capital expenditures linked to the building of new capacity, refinancing of remaining debt and working capital for general purposes.

CEO Ilan Sobel said: "This represents a pivotal capital markets milestone for BioHarvest, helping to fortify our balance sheet by adding incremental cash and significantly reducing our debt levels, while concurrently providing us with the financial flexibility to accelerate our growth initiatives across both our Products and CDMO services divisions. I look forward to continued operational execution in the months ahead as we strive to create value for our shareholders."

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts. Readers are cautioned that future contracts or increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
(604) 622-1186
info@bioharvest.com

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
BHST@mzgroup.us

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267359

FAQ

How much did BioHarvest (BHST) raise in their latest financing round?

BioHarvest raised $10.9 million in gross proceeds through warrant exercises and convertible note issuances, while also reducing debt by $3.8 million.

What is BioHarvest's (BHST) current debt level after the transaction?

Following the transaction, BioHarvest's total debt stands at $6.6 million, consisting of $3.6 million in short-term debt and $3 million in long-term debt.

How will BioHarvest (BHST) use the proceeds from this financing?

The $10.9 million proceeds will be used for capital expenditures related to building new capacity, refinancing of remaining debt, and working capital for general purposes.

What was the price offered to warrant holders in BioHarvest's (BHST) transaction?

BioHarvest offered warrant holders and convertible loan holders a reduced price of $6.50 per share, representing a modest discount to the 90-day trading average.

How many shares were issued in BioHarvest's (BHST) financing transaction?

A total of 2,259,666 ordinary shares were issued, including 1,113,192 from warrant exercises, 1,058,261 from convertible note conversions, and 88,213 for short-term debt repayment.